<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13292">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933879</url>
  </required_header>
  <id_info>
    <org_study_id>NVXT 1404</org_study_id>
    <nct_id>NCT02933879</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b
      Clinical Study to Assess the Efficacy, Safety and Tolerability of 8-Week Regimens of NVXT
      topical product in Patients with Mild to Moderate Onychomycosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate safety and tolerability of the two regimens of NVXT (Treatment Groups A and B) in
      patients with mild to moderate distal subungual onychomycosis of the target toenail.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients in each treatment group with a complete therapeutic cure</measure>
    <time_frame>day 365</time_frame>
    <description>Complete therapeutic cure is defined as both complete clinical and mycological cure of the target toenail</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients in each treatment group with a complete or almost complete therapeutic cure</measure>
    <time_frame>day 365</time_frame>
    <description>Almost complete therapeutic cure is defined as both mycological and satisfactory clinical cure of the target toenail</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients in each treatment group with a mycological cure</measure>
    <time_frame>day 365</time_frame>
    <description>Mycological cure is defined as a negative KOH test and a negative fungal culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients in each treatment group with a complete clinical cure</measure>
    <time_frame>day 365</time_frame>
    <description>Complete clinical cure is defined as 0% nail involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients in each treatment group with a satisfactory clinical cure</measure>
    <time_frame>day 365</time_frame>
    <description>Satisfactory clinical cure is defined as &lt;5% of the target toenail involvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>NVXT topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo topical</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVXT topical</intervention_name>
    <description>topical treatment</description>
    <arm_group_label>NVXT topical</arm_group_label>
    <other_name>Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Vehicle) Topical</intervention_name>
    <description>topical treatment</description>
    <arm_group_label>Placebo topical</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of onychomycosis of the target toenail (defined as one of the
             infected great toenails).

        Exclusion Criteria:

          -  Females who are pregnant, lactating or likely to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals U.S.A., Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taro Pharmaceuticals USA Inc.</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>October 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
